Radius Pharmaceuticals (RDUS) - Long-Term Debt to Capital Coefficient

Radius Recycling, Inc. (RDUS) is establishing strategic partnerships with municipal services and plants to implement circular economy principles. The company's financial results are heavily dependent on global steel prices and industrial cycles, remaining vulnerable to crises. Meanwhile, the biopharmaceutical base is actively developing drugs through contract manufacturing, and the metric stands at 1.06. This price chart on the GURU.Markets platform clearly illustrates the asset's current price action.

This indicator assesses financial stability by comparing long-term credit obligations to the company's net equity. By analyzing the ratio of long-term liabilities to equity, an investor determines the business's degree of dependence on external borrowing. The calculation is based on dividing the total debt with a maturity of more than one year by the shareholders' equity. For Radius Recycling, Inc. (RDUS), such a borrowing structure optimizes the development of the biopharmaceutical ecosystem. The patent portfolio and stable contracts minimize risks when servicing the debt load.